The role of PPAR-alpha agonists in the prevention of CVD in diabetes.
Taskinen
Marja-Riitta
MR
Department of Medicine, Division of Cardiology, Helsinki University Hospital, Biomedicum, Haartmaninkatu 8, P.O. Box 700, 00029 Helsinki, Finland. Marja-Riitta.Taskinen@helsinki.fi
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications* / Q000517:prevention & control*; D002995:Clofibric Acid / Q000494:pharmacology* / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006801:Humans; D047493:PPAR alpha / Q000819:agonists*; D016032:Randomized Controlled Trials as Topic
D000924:Anticholesteremic Agents; D047493:PPAR alpha; D002995:Clofibric Acid